摘要
目的 探讨过氧化酶体增生物激活受体γ(PPARγ)配体罗格列酮对小鼠体内人类胃癌MGC803细胞移植瘤生长的影响.方法 建立人类胃癌MGC803细胞小鼠肾囊膜下移植瘤模型,通过解剖显微镜和HE染色观察50 mg/kg的罗格列酮连续灌胃5 d作用于荷瘤小鼠后对移植瘤生长的抑制作用.结果 50 mg/kg的罗格列酮能明显抑N4,鼠肾囊膜下移植瘤MGC803细胞增生、诱导肿瘤细胞凋亡而抑制移植瘤的生长,抑瘤率达62.9%.结论 PPARγ配体罗格列酮能抑制小鼠体内肾囊膜下MGC803细胞移植瘤生长.
Objective To investigate the inhibitory effects of PPARγ ligand rosiglitazone in vivo of mice which were transplanted the human gastric carcinoma cells line MGC803 into subrenal-capsule.Methods To establish kunming mouse tumor modles of MGC803 cells transplanted into subrenal-capsule and assay the inhibiting growth effects of 50 mg/kg rosiglitazone which were continuously poured into mice gastric for five days by the dissect microscope and HE stain.Results Rosiglitazone could inhibit the growth of MGC803 cells transplanted into subrenal-capsule of mice in vivo by inhibiting proliferation and inducting apoptosis,the tumor inhibitory rate was 62.9%.Conclusion PPARγ ligand rosiglitazone can inhibit the growth of MGC803 cells transplanted into subrenal-capsule of mice in vivo.
出处
《肿瘤研究与临床》
CAS
2008年第3期155-157,共3页
Cancer Research and Clinic
基金
湖南省卫生厅资助课题(C2003-015)